Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Sep 17, 2022 1:15pm
119 Views
Post# 34969029

RE:RE:RE:RE:RE:RBC's aftermarket dump

RE:RE:RE:RE:RE:RBC's aftermarket dump

You are reading a lot into the word "nicely". I'd say it's a word that Paul hopes will stick in somebody's mind, it clearly did if that somebody passed it on to SPCEO, but which commits to absolutely nothing as SPCEO points out. Job done Paul, just how every biotech exec needs to talk at some moments. There will be, and have been, other times when his words have more meaning. And some times when they have very precise meanings. Those are the ones to watch out for.


Trogarzon wrote: The simple fact they are waisting time in Montreal and Toronto is telling me they have to resort to this for the simple fact the Plan A (US only deal) ain't working out for now.. so much of the same and a OO no.2 for shure.  Having Paul stating that the 1b is going Nicely sounds weak to me.. very weak.  Sounds like they are having issues and digging new questions instead of finding new answers.  Now they'll want to finance their quest for answers on the basis of having more questions and no clear answers for the time being.  Something like that will result in 2.50$ raise with a 3$ warrant (a full one this time) and complaints from much diluted shareholders for the next five years.  I'll bet my life on it anytime. GLTA...

 

<< Previous
Bullboard Posts
Next >>